Summary of effects of IL-2 monotherapy on LFS and OS in various subsets*
| Strata . | LFS . | OS . | ||||
|---|---|---|---|---|---|---|
| Subset HR (95% CI) . | Test of treatment effect in subset . | Test of treatment by subset interaction . | Subset HR (95% CI) . | Test of treatment effect in subset . | Test of treatment by subset interaction . | |
| Age < 21 y | 1.11 (0.78, 1.57) | P = .56 | 1.05 (0.68, 1,64) | P = .82 | ||
| Age 21-60 y | 0.93 (0.71, 1.22) | P = .61 | P = .69 | 0.99 (0.73, 1.35) | P = .95 | P = .75 |
| Age > 60 y | 0.93 (0.71, 1.22) | P = .59 | 1.16 (0.88, 1.54) | P = .29 | ||
| Male | 0.93 (0.74, 1.17) | P = .54 | 1.05 (0.81, 1.35) | P = .72 | ||
| Female | 1.02 (0.80, 1.32) | P = .85 | P = .58 | 1.17 (0.88, 1.56) | P = .28 | P = .57 |
| ECOG performance status 0-1 | 0.88 (0.71, 1.10) | P = .27 | 1.11 (0.87, 1.41) | P = .40 | ||
| ECOG performance status other | 0.95 (0.55, 1.64) | P = .87 | P = .79 | 0.96 (0.53, 1.76) | P = .90 | P = .46 |
| Karyotype favorable | 0.84 (0.54, 1.29) | P = .42 | 0.98 (0.59, 1.63) | P = .94 | ||
| Karyotype intermediate | 1.05 (0.83, 1.33) | P = .68 | P = .40 | 1.12 (0.86, 1.46) | P = .39 | P = .80 |
| Karyotype unfavorable | 0.58 (0.28, 1.18) | P = .13 | 0.86 (0.41, 1.80) | P = .69 | ||
| Karyotype unknown | 0.93 (0.66, 1.30) | P = .65 | 0.93 (0.63, 1.35) | P = .69 | ||
| AML subtype M0-M5-M6-M7 | 0.98 (0.70, 1.36) | P = .88 | 0.90 (0.62, 1.31) | P = .60 | ||
| AML subtype M1-M2-M4 | 1.00 (0.82, 1.23) | P = .97 | P = .58 | 1.21 (0.97, 1.52) | P = .09 | P = .24 |
| AML subtype other or unknown | 0.57 (0.20, 1.61) | P = .29 | 0.64 (0.22, 1.82) | P = .40 | ||
| Months from CR ≤ 4 mo | 0.94 (0.76, 1.16) | P = .56 | 1.09 (0.87, 1.38) | P = .46 | ||
| Months from CR > 4 mo | 1.08 (0.82, 1.42) | P = .60 | P = .43 | 1.12 (0.81, 1.55) | P = .49 | P = .90 |
| Strata . | LFS . | OS . | ||||
|---|---|---|---|---|---|---|
| Subset HR (95% CI) . | Test of treatment effect in subset . | Test of treatment by subset interaction . | Subset HR (95% CI) . | Test of treatment effect in subset . | Test of treatment by subset interaction . | |
| Age < 21 y | 1.11 (0.78, 1.57) | P = .56 | 1.05 (0.68, 1,64) | P = .82 | ||
| Age 21-60 y | 0.93 (0.71, 1.22) | P = .61 | P = .69 | 0.99 (0.73, 1.35) | P = .95 | P = .75 |
| Age > 60 y | 0.93 (0.71, 1.22) | P = .59 | 1.16 (0.88, 1.54) | P = .29 | ||
| Male | 0.93 (0.74, 1.17) | P = .54 | 1.05 (0.81, 1.35) | P = .72 | ||
| Female | 1.02 (0.80, 1.32) | P = .85 | P = .58 | 1.17 (0.88, 1.56) | P = .28 | P = .57 |
| ECOG performance status 0-1 | 0.88 (0.71, 1.10) | P = .27 | 1.11 (0.87, 1.41) | P = .40 | ||
| ECOG performance status other | 0.95 (0.55, 1.64) | P = .87 | P = .79 | 0.96 (0.53, 1.76) | P = .90 | P = .46 |
| Karyotype favorable | 0.84 (0.54, 1.29) | P = .42 | 0.98 (0.59, 1.63) | P = .94 | ||
| Karyotype intermediate | 1.05 (0.83, 1.33) | P = .68 | P = .40 | 1.12 (0.86, 1.46) | P = .39 | P = .80 |
| Karyotype unfavorable | 0.58 (0.28, 1.18) | P = .13 | 0.86 (0.41, 1.80) | P = .69 | ||
| Karyotype unknown | 0.93 (0.66, 1.30) | P = .65 | 0.93 (0.63, 1.35) | P = .69 | ||
| AML subtype M0-M5-M6-M7 | 0.98 (0.70, 1.36) | P = .88 | 0.90 (0.62, 1.31) | P = .60 | ||
| AML subtype M1-M2-M4 | 1.00 (0.82, 1.23) | P = .97 | P = .58 | 1.21 (0.97, 1.52) | P = .09 | P = .24 |
| AML subtype other or unknown | 0.57 (0.20, 1.61) | P = .29 | 0.64 (0.22, 1.82) | P = .40 | ||
| Months from CR ≤ 4 mo | 0.94 (0.76, 1.16) | P = .56 | 1.09 (0.87, 1.38) | P = .46 | ||
| Months from CR > 4 mo | 1.08 (0.82, 1.42) | P = .60 | P = .43 | 1.12 (0.81, 1.55) | P = .49 | P = .90 |
See supplemental figures for forest plots of subset analyses.